EP12.02 LOW GRADE GLIOMAS. REVIEW IN OUR CENTER

Abstract BACKGROUND Low-grade gliomas (LGG) represent a significant challenge for clinicians due to their location in critical brain areas and the diagnosis at younger ages than other brain tumors. Over the past few decades our understanding of these tumors has advanced considerably, but a significant gap remains regarding prognostic factors and optimal therapeutic strategies. This retrospective analysis seeks to shed light on the clinical, radiological, and molecular patterns associated with these tumors, with the goal of identifying factors that may influence therapeutic decisions. MATERIAL AND METHODS This is a retrospective descriptive study of 58 patients with an histologic confirmed LGG treated in our center between 2018 and 2023. Primary endpoints were overall survival (OS) stratified by glioma type, grade and type of surgery, and disease-free survival (DFS) stratified by adjuvant treatment. RESULTS We treated 39 women and 19 men, median age at diagnosis was 43 years (min 21 - max 79). A 53.4% were astrocytomas and 46.6% were oligodendrogliomas. A 75.9% were grade 2 and a 24.1% were grade 3. IDH-mutation was found in 53 patients (98,1%). Fourty-three percent had a complete resection (CR), 50% had a subtotal resection (STR) and 6,9% had only a biopsy. Seven (28%) of the patients with CR received adjuvant treatment. Of the 29 with STR, 24 (82.8%) received adjuvant treatment. Adjuvant treatment was radiotheraphy in 33 patients and chemotherapy in 27. It was given concomitantly in 13 cases. With a median follow - up of 48,5 months (IQR 55), 23 patients (46%) had a local relapse and 10 (17,2%) died. OS was higher in oligodendrogliomas (mean 106,4 vs 192,1 months; p = 0.038) and in grade 2 tumors (mean 164,3 vs 51,0 months; p < 0,01). There were no diference in OS between CR and STR. DFS was higher with adjuvant treatment (median 61 vs 31 months; p = 0.039). CONCLUSIONS This retrospective analysis highlights the heterogeneity and complexity of low-grade gliomas. Our data confirm that oligodendrogliomas and WHO grade 2 tumors are associated with significantly better overall survival. Interestingly, the extent of resection did not significantly impact survival outcomes, emphasizing the importance of a tailored approach when balancing resection with neurological risk. Moreover, adjuvant treatment was associated with longer disease-free survival, particularly in patients with subtotal resection. These findings support the role of molecular profiling and individualized treatment strategies in optimizing outcomes for patients with LGG. <!--EndFragment-->